CHP
ONCY

Cable Hill Partners’s Oncolytics Biotech ONCY Stock Holding History

Cable Hill Partners’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-157
Closed -$1K – 838
2018
Q2 		$1K Buy
+157
New +$967 ﹤0.01% 867

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

Cable Hill Partners's ONCY Position: Q3 2018 in Review

Cable Hill Partners sold out of Oncolytics Biotech (ONCY) in Q3 2018, closing a stake of 157 shares — an estimated $1K sold.

Cable Hill Partners first reported a position in ONCY in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 21 funds tracked by Wall St. Rank hold ONCY as of Q3 2018.

  • Cable Hill Partners reported no remaining Oncolytics Biotech position as of Q3 2018 after selling out during the quarter.
  • Cable Hill Partners sold 157 Oncolytics Biotech shares in Q3 2018, an estimated $1K.
  • Cable Hill Partners first reported a position in Oncolytics Biotech in Q2 2018 and held it in 1 quarter.
  • Cable Hill Partners's Oncolytics Biotech position peaked at $1K in Q2 2018.
  • 21 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2018.

Based on Cable Hill Partners's 13F filing for Q3 2018, filed 14 Nov 2018.